Renal Cancer Clinical Pipeline | 75+ Companies, Including Genentech, AstraZeneca, Allogene Therapeutics, and Merck Driving the Next Breakthroughs

The Renal Cancer market is evolving with cutting-edge research and new therapeutic advancements.

DelveInsight's 'Renal Cancer Pipeline Insight 2024' report provides comprehensive global coverage of pipeline Renal Cancer therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Renal Cancer pipeline domain.

For Renal Cancer emerging drugs, the Renal Cancer pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Renal Cancer Pipeline Report
• DelveInsight's Renal Cancer Pipeline analysis depicts a robust space with 75+ active players working to develop 80+ pipeline drugs for Renal Cancer treatment.
• The leading Renal Cancer companies include Genentech, AstraZeneca, Allogene Therapeutics, Merck & Co., Inc, X4 Pharmaceuticals, Argos Therapeutics, Pfizer, Eisai Inc., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, AVEO Pharmaceuticals, Inc, Mabwell (Shanghai) Bioscience Co., Ltd., Beijing Scitech-Mq Pharmaceuticals Limited, Qilu Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd., and others are evaluating their lead assets to improve the Renal Cancer treatment landscape.
• Key Renal Cancer pipeline therapies in various stages of development include Belzutifan/Everolimus, Orellanine, Atezolizumab/Cabozantinib, HB0025, ADI-270, IPI-549/Bevacizumab, APL-101 Oral Capsules, MDX2001, Olaparib, MK-4830, ALLO-316, and others.
• In Feb 2025, Telix Pharmaceuticals announced that the FDA accepted the Biologics License Application (BLA) for TLX250-CDx (Zircaix®), a breakthrough kidney cancer PET imaging agent. The FDA granted a Priority Review and set a PDUFA date of August 27, 2025, for a potential U.S. launch.

Request a sample and discover the recent breakthroughs happening in the Renal Cancer pipeline landscape @ https://www.delveinsight.com/report-store/renal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Renal Cancer Overview
Renal cell carcinoma (RCC), also known as hypernephroma, renal adenocarcinoma, or kidney cancer, is a malignancy that originates in the tubules of the kidney. In its early stages, RCC is often asymptomatic, but as it progresses, symptoms may include abdominal lumps, fatigue, unexplained weight loss, blood in the urine, appetite loss, vision problems, and excessive hair growth. RCC accounts for approximately 85% of adult kidney cancers and remains clinically silent for much of its course. Only about 10% of patients present with the classic triad of flank pain, hematuria, and flank mass, while roughly 33% of cases develop metastatic spread, complicating treatment due to the limited efficacy of current therapies.

As RCC advances, symptoms such as lower back pain, fever, night sweats, and high blood pressure may appear. Several risk factors contribute to RCC, including obesity, smoking, chronic kidney disease, genetic predisposition, high blood pressure, thyroid cancer, and diabetes. Diagnosis involves physical examinations, CT scans, blood tests, urine analysis, and biopsies. Treatment strategies include targeted therapies that inhibit tumor growth by blocking specific proteins or blood vessels, using drugs such as axitinib, bevacizumab, cabozantinib, everolimus, lenvatinib, nivolumab, pazopanib, sorafenib, sunitinib, and temsirolimus. Immunotherapy and chemotherapy also play roles in RCC management, with a focus on improving patient outcomes and controlling disease progression.

Find out more about Renal Cancer medication @ https://www.delveinsight.com/report-store/renal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Renal Cancer Treatment Analysis: Drug Profile
Atezolizumab : Genentech
Atezolizumab is a monoclonal antibody. It is designed to bind with a protein called PD-L1 expressed on tumor cells and tumor-infiltrating immune cells by blocking its interactions with both PD-1 and B7.1 the drug candidate are programmed cell death-1 ligand-1 inhibitors. Currently it is in Phase III stage of clinical trial evaluation to treat Renal Cancer.

Olaparib: AstraZeneca
Olaparib is a potent and orally active poly (ADP-ribose) polymerase PARP inhibitor thereby blocking the repair of single-strand DNA breaks resulting in synthetic lethality in BRCA-associated cancer cells, which have a dysfunction of another DNA repair pathway - homologous recombination being developed for the treatment of renal cell carcinoma. Currently being evaluated in the Phase II studies.

MK-4830 : Merck & Co., Inc
MK-4830 is an investigational first-in-class human monoclonal antibody that inhibits the binding of immunoglobulin-like transcript 4 (ILT-4) to its ligands. The drug candidate is being developed in combination with KEYTRUDA. MK-4830 is being developed under an agreement with Agenus Inc. Currently the drug is being evaluated in Phase II for the treatment of Renal Cancer.

Key Renal Cancer Therapies and Companies
• Belzutifan/Everolimus: Merck Sharp & Dohme LLC
• Orellanine: Oncorena AB
• Atezolizumab/Cabozantinib: Hoffmann-La Roche
• HB0025: Huabo Biopharm Co., Ltd.
• ADI-270: Adicet Therapeutics
• IPI-549/Bevacizumab: Infinity Pharmaceuticals, Inc.
• APL-101 Oral Capsules: Apollomics Inc.
• MDX2001: ModeX Therapeutics
• Olaparib: AstraZeneca
• MK-4830 : Merck & Co., Inc
• ALLO-316 : Allogene Therapeutics

Learn more about the novel and emerging Renal Cancer pipeline therapies @ https://www.delveinsight.com/report-store/renal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Renal Cancer Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the Renal Cancer Pipeline Report
• Coverage: Global
• Key Renal Cancer Companies: Genentech, AstraZeneca, Allogene Therapeutics, Merck & Co., Inc, X4 Pharmaceuticals, Argos Therapeutics, Pfizer, Eisai Inc., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, AVEO Pharmaceuticals, Inc, Mabwell (Shanghai) Bioscience Co., Ltd., Beijing Scitech-Mq Pharmaceuticals Limited, Qilu Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd., and others.
• Key Renal Cancer Pipeline Therapies: Belzutifan/Everolimus, Orellanine, Atezolizumab/Cabozantinib, HB0025, ADI-270, IPI-549/Bevacizumab, APL-101 Oral Capsules, MDX2001, Olaparib, MK-4830, ALLO-316, and others.

Dive deep into rich insights for drugs used for Renal Cancer treatment; visit @ https://www.delveinsight.com/report-store/renal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Renal Cancer Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Renal Cancer Pipeline Therapeutics
6. Renal Cancer Pipeline: Late-Stage Products (Phase III)
7. Renal Cancer Pipeline: Late-Stage Products (Phase III)
8. Renal Cancer Pipeline: Mid-Stage Products (Phase II)
9. Renal Cancer Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.